Abstract
Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 253-275 |
| Number of pages | 23 |
| Journal | Expert opinion on biological therapy |
| Volume | 1 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiogenesis
- Cancer therapy
- Carboxyamido-triazole
- Endostatin
- IL-12
- Matrix metalloproteinases
- Sitramin
- Thalidomide
- VEGF
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry
Fingerprint
Dive into the research topics of 'General aspects of anti-angiogenesis and cancer therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS